{
    "clinical_study": {
        "@rank": "153148", 
        "brief_summary": {
            "textblock": "Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of\n      the present cohort study is to investigate whether ACEi therapy reduces  the rate of\n      periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention\n      (PCI) among patients with metabolic syndrome."
        }, 
        "brief_title": "Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction", 
        "condition": [
            "Metabolic Syndrome", 
            "Coronary Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Infarction", 
                "Myocardial Infarction", 
                "Metabolic Syndrome X"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. metabolic syndrome\n\n          2. elective percutaneous coronary intervention with angiographically successful stent\n             implantation\n\n        Exclusion Criteria:\n\n          1. acute coronary events\n\n          2. renal failure\n\n          3. needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded\n\n          4. left main coronary artery disease\n\n          5. chronic total occlusion\n\n          6. high levels of baseline CKMB or troponin\n\n          7. any contraindication of aspirin, clopidogrel or ACEi treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Metabolic syndorme (MS) was defined as the presence of 3 or more of these components:\n\n          1. high fasting glucose (fasting serum glucose \u2265100 mg/dl or drug treatment for elevated\n             blood glucose)\n\n          2. abdominal obesity (given as waist circumference >102 cm in men and >88 cm in women)\n\n          3. high blood pressure (>130/>85 mmHg or drug treatment for hypertension)\n\n          4. hypertriglyceridemia (serum triglycerides \u2265150 mg/dl)\n\n          5. low high-density lipoprotein (HDL) cholesterol (<40 mg/dl in men and <50 mg/dl in\n             women)."
            }
        }, 
        "enrollment": {
            "#text": "410", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054390", 
            "org_study_id": "ACEmetsend"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin-Converting Enzyme Inhibitors", 
                "Enzyme Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Angiotensin converting enzyme inhibitor", 
            "inflammation", 
            "metabolic syndrome", 
            "myonecrosis", 
            "percutaneous coronary intervention", 
            "periprocedural myocardial injury"
        ], 
        "lastchanged_date": "April 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey", 
                    "zip": "06230"
                }, 
                "name": "Ankara University School Of Medicine, Department of Cardiology"
            }, 
            "investigator": {
                "last_name": "Ozgur U Ozcan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_groups": "1", 
        "official_title": "Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome", 
        "other_outcome": {
            "description": "high sensitive C-reactive protein measurement 24 hours after PCI", 
            "measure": "inflammatory marker", 
            "safety_issue": "No", 
            "time_frame": "24 hours after PCI"
        }, 
        "overall_contact": {
            "email": "ozgurulasozcan@yahoo.com.tr", 
            "last_name": "Ozgur U Ozcan, MD", 
            "phone": "00903125082410"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Periprocedural MI was defined as cardiac Troponin I release [5 times ULN] 24 hours after percutaneous coronary intervention", 
            "measure": "Periprocedural myocardial injury (MI)", 
            "safety_issue": "No", 
            "time_frame": "24 hours after (percutaneous coroary intervention) PCI"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054390"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ankara University", 
            "investigator_full_name": "\u00d6zg\u00fcr Ula\u015f \u00d6zcan", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Peri-procedural myonecrosis was defined as troponin I release of >1\u00d7ULN 24 hours after the intervention.", 
            "measure": "Periprocedural myonecrosis", 
            "safety_issue": "No", 
            "time_frame": "24 hours after PCI"
        }, 
        "source": "Ankara University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ankara University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}